AzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access Event

Rhea-AI Summary

AzurRx BioPharma (NASDAQ: AZRX) will participate in the 10th Annual LifeSci Partners Corporate Access Event from January 6-8 and 11-14, 2021. James Sapirstein, President & CEO, will engage in virtual one-on-one meetings with investors and pharma companies, discussing the company’s business, clinical programs, and upcoming milestones for 2021. AzurRx focuses on innovative, non-systemic therapies for gastrointestinal diseases, with key products targeting exocrine pancreatic insufficiency and COVID-19 gastrointestinal infections.

DELRAY BEACH, Fla., Jan. 05, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will participate in the 10^th Annual LifeSci Partners Corporate Access Event.

James Sapirstein, President & CEO of AzurRx BioPharma will be participating in virtual one-on-one meetings with registered investors and pharmaceutical companies. Mr. Sapirstein will be available to provide an overview of the Company’s business and clinical development programs and discuss anticipated 2021 milestones.

Event:	10th Annual LifeSci Partners Corporate Access Event
Dates:	January 6-8 & 11-14, 2021
Registration:	www.lifesciadvisors.com

About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets: MS1819 – a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis – with two ongoing Phase 2 clinical trials; and two clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor;  FW-420, for the treatment of grade 1 Immune Checkpoint Inhibitor Associated Colitis (ICI-AC) and diarrhea in oncology patients and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. Additional information on the Company can be found at www.azurrx.com.

For more information:

AzurRx BioPharma, Inc.
1615 South Congress Avenue
Suite 103
Delray Beach, Florida 33445
Phone: (646) 699-7855
info@azurrx.com

Investor Relations contact:

LifeSci Advisors, LLC. 
Hans Vitzthum, Managing Director 
1 International Place, Suite 1480 
Boston, MA 02110 
Phone: (617) 430-7578 
hans@lifesciadvisors.com

FAQ

When is AzurRx participating in the LifeSci Partners Corporate Access Event?

AzurRx will participate from January 6-8 and January 11-14, 2021.

Who will represent AzurRx at the Corporate Access Event?

James Sapirstein, President & CEO, will represent AzurRx.

What is the focus of AzurRx BioPharma's research?

AzurRx focuses on non-systemic therapies for gastrointestinal diseases.

What key products is AzurRx developing?

AzurRx is developing therapies for exocrine pancreatic insufficiency and COVID-19 gastrointestinal infections.

Where is AzurRx BioPharma located?

AzurRx BioPharma is headquartered in Delray Beach, Florida.